Enhanced syngeneic tumor destruction by in vivo inhibition of suppressor T cells using anti-I-J alloantiserum
- PMID: 307911
- PMCID: PMC2018300
Enhanced syngeneic tumor destruction by in vivo inhibition of suppressor T cells using anti-I-J alloantiserum
Abstract
The cellular response to a methylcholanthrene-induced sarcoma S1509a has been investigated. Histologic analysis of the in vivo response to S1509a included a study of tumor development in nonimmune, tumor immune, or hyerimmune syngeneic mice, as well as in nonimmune animals treated with antiserum produced to interact solely with determinants encoded by the I-J subregion of the H-2 major histocompatibility complex. Tumors from immune or hyperimmune mice showed marked infiltration by mononuclear and, to a lesser extent, polymorphonuclear cells, with marked tumor cell necrosis. Anti-I-J treated mice displayed similar but quantitatively reduced leukocytic infiltrates and less evidence of tumor cell degeneration. Untreated nonimmune mice, on the other hand, revealed only mild leukocytic infiltration with little or no necrosis of the tumor. Thus, the administration of anti-I-J antiserum, which has been shown to diminish suppressor cell activity, is associated with increased leukocytic infiltration and enhanced syngeneic tumor destruction in vivo in the nonimmune host.
Similar articles
-
Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells in vivo.J Immunol. 1978 Dec;121(6):2144-7. J Immunol. 1978. PMID: 82578
-
Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.Lab Invest. 1985 Mar;52(3):304-13. Lab Invest. 1985. PMID: 3974201
-
The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.Jpn J Cancer Res. 1986 Aug;77(8):825-32. Jpn J Cancer Res. 1986. PMID: 3093429
-
Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts.J Immunol. 1977 Aug;119(2):757-64. J Immunol. 1977. PMID: 69667
-
Differential antigen presentation in tumor immunity.Fed Proc. 1984 Jun;43(9):2460-4. Fed Proc. 1984. PMID: 6327399 Review.
Cited by
-
Atopy--a favourable prognostic factor for survival in Hodgkin's disease.Br J Cancer. 1983 Aug;48(2):209-15. doi: 10.1038/bjc.1983.176. Br J Cancer. 1983. PMID: 6882661 Free PMC article.
-
Specific adoptive immunotherapy: experimental basis and future potential.Surv Immunol Res. 1982;1(1):85-90. doi: 10.1007/BF02918244. Surv Immunol Res. 1982. PMID: 6764836 Review. No abstract available.
-
Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera.Proc Natl Acad Sci U S A. 1979 Feb;76(2):920-4. doi: 10.1073/pnas.76.2.920. Proc Natl Acad Sci U S A. 1979. PMID: 106399 Free PMC article.
-
Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells.Proc Natl Acad Sci U S A. 1981 Mar;78(3):1809-12. doi: 10.1073/pnas.78.3.1809. Proc Natl Acad Sci U S A. 1981. PMID: 6453350 Free PMC article.
-
Regulation of the immune response to antigens on the malignant cell surface.Springer Semin Immunopathol. 1982;5(2):175-92. doi: 10.1007/BF00199795. Springer Semin Immunopathol. 1982. PMID: 6293112 Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources